Collplant

The core of CollPlant's business is its proprietary technology for producing recombinant human Type I collagen (rhCollagen) from genetically engineered tobacco plants. This plant-based method allows for the mass production of collagen that is identical to the collagen produced by the human body, positioning it as a fundamental building block for regenerative medicine applications. The company operates in the regenerative and aesthetic medicine markets, serving clients in tissue repair, aesthetics, and organ manufacturing. Its business model revolves around the development and commercialization of products derived from its rhCollagen platform, with revenue generated through product sales, collaborations, and licensing agreements with major industry players like AbbVie and United Therapeutics.

CollPlant's product pipeline is diverse, targeting high-value medical needs. A key offering is its BioInk platform, Collink.3D™, which is designed for the 3D bioprinting of tissues and organs. This technology is being leveraged to develop regenerative breast implants, which are intended to provide a safer alternative to silicone implants by having the bioprinted scaffold degrade over time and be replaced by the patient's own natural tissue. The company has successfully printed commercial-size 200cc implants and is advancing this program through large animal studies. In addition to bioprinting, CollPlant has developed products for medical aesthetics, including dermal and soft tissue fillers in partnership with Allergan, an AbbVie company. It also commercializes products in Europe, such as VergenixSTR for treating tendinopathy and VergenixFG for wound healing.